Search Within

Christine Anne Pratilas

Formats
  1. Journal Article (25)
  2. Meeting Abstract (25)
Groups
  1. Department of Medicine (45)
  2. GSK Faculty (44)
  3. Solid Tumor Oncology Division (43)
  4. Human Oncology and Pathogenesis Program (38)
  5. Sloan Kettering Institute Faculty (37)
  6. Breast Medicine Service (36)

More Groups

People
  1. Neal Rosen (36)
  2. David Solit (34)
  3. Barry Taylor (11)
  4. Yogindra Persaud (10)
  5. Ayana Sawai (9)
  6. Madhavi Tadi (9)

More People

Years
  1. 2015 (6)
  2. 2014 (4)
  3. 2013 (2)
  4. 2012 (6)
  5. 2011 (3)
  6. 2010 (6)

More Years

Publications
  1. Cancer Research (22)
  2. Clinical Cancer Research (4)
  3. Journal of Clinical Oncology (3)
  4. Cancer Discovery (2)
  5. Pediatric Blood and Cancer (2)
  6. Proceedings of the National Academy of Sciences of the United States of America (2)

More Publications

Publishers
  1. American Association for Cancer Research (30)
  2. Nature Publishing Group (4)
  3. American Society of Clinical Oncology (3)
  4. Cell Press (2)
  5. National Academy of Sciences (2)
  6. Oxford University Press (2)

More Publishers

Results (50)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • FLT PET as a non-invasive marker of response to MEK inhibition
    Meeting Abstract

    Solit, D. B.; Santos, E.; Pratilas, C. A.; Moroz, M.; Blasberg, R.; Sebolt-Leopold, J.; Larson, S.; Rosen, N.
    Cancer Research (2006)

    Fulltext@MSK | Save
  • MAPK activation by B-RAF mutation or tyrosine kinase activation is associated with different patterns of feedback regulation that correlate with functional output of the pathway
    Meeting Abstract

    Pratilas, C. A.; Grbovic, O.; Sebolt-Leopold, J.; Rosen, N.; Solit, D. B.
    Cancer Research (2006)

    Fulltext@MSK | Save
  • B-RAF mutation is associated with altered patterns of negative feedback of MAPK signaling that correlate with increased output of the pathway and increased sensitivity to MEK inhibition
    Meeting Abstract

    Pratilas, C.; Grbovic, O.; Zhao, H.; Viale, A.; Solit, D.; Rosen, N.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • BRAF mutation predicts sensitivity to MEK inhibition
    Journal Article

    Solit, D. B.; Garraway, L. A.; Pratilas, C. A.; Sawai, A.; Getz, G.; Basso, A.; Ye, Q.; Lobo, J. M.; She, Y.; Osman, I.; more...
    Nature (2006)

    Fulltext@MSK | Save
  • Cyclin D expression and G1 progression are dependent on MEK MAP kinase activity in tumor cells with B-Raf mutation but not in breast cancer cells with wild type Ras and Raf
    Meeting Abstract

    Sawai, A.; Pratilas, C.; Basso, A.; Rosen, N.; Solit, D. B.
    Cancer Research (2005)

    Fulltext@MSK | Save
  • The MEK inhibitor PD0325901 completely inhibits the growth of melanoma tumors with mutationally activated B-Raf
    Meeting Abstract

    Pratilas, C.; Sawai, A.; Ye, Q.; Lobo, J.; She, Y.; Sebolt-Leopold, J.; Rosen, N.; Solit, D.
    Cancer Research (2005)

    Fulltext@MSK | Save
  • FLT PET as a non-invasive marker of response to MEK inhibition
    Meeting Abstract

    Solit, D. B.; Santos, E.; Pratilas, C.; Moroz, M.; Blasberg, R.; Sebolt-Leopold, J.; Larson, S. M.; Rosen, N.
    Clinical Cancer Research (2005)

    Fulltext@MSK | Save
  • Cyclin D expression and G1 progression are dependent on MEK-MAP kinase activity in tumor cells with B-Raf mutation but not in breast cancer cells with wild type Ras and Raf
    Meeting Abstract

    Pratilas, C. A.; Grbovic, O.; Basso, A. D.; Sawai, A.; Chapman, P.; Rosen, N.; Solit, D. B.
    Cancer Research (2004)

    Fulltext@MSK | Save
  • New efficient synthesis of resorcinylic macrolides via ynolides: Establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the target
    Journal Article

    Yang, Z. Q.; Geng, X.; Solit, D.; Pratilas, C. A.; Rosen, N.; Danishefsky, S. J.
    Journal of the American Chemical Society (2004)

    Fulltext@MSK | Save
  • Cyclin D expression and G1 progression are dependent on MEK-MAP kinase activity in tumor cells with B-Raf mutation but not in breast cancer cells with wild type Ras
    Meeting Abstract

    Sawai, A.; Basso, A. D.; Solit, D. B.; She, Q. B.; Grbovic, O.; Pratilas, C.; Chapman, P.; Moasser, M. M.; Rosen, N.
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save